TrialNature medicine2024

CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.

E William St Clair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.